The earnings call highlighted significant positive developments, including successful trial results for D-PLEX100 and a strengthened financial position, despite increased expenses and technical issues during the call.

Company Guidance

During PolyPid's second quarter 2025 earnings call, the company provided several key metrics and guidance for its D-PLEX100 program and financial outlook. The SHIELD II Phase III trial results demonstrated a 58% reduction in surgical site infections (SSI) compared to the standard of care, with significant reduction in deep SSIs. The trial also showed a 62% reduction in patients with an ASEPSIS score over 20, indicating less severe infection appearances. PolyPid plans to submit a New Drug Application (NDA) to the FDA in early 2026 and a Marketing Authorization Application (MAA) in Europe shortly thereafter. Financially, the company improved its cash position to $29.5 million as of June 30, 2025, and expects its cash runway to extend well into 2026. The company also announced progress in its GLP-1 program aimed at the metabolic disease market, and it anticipates further developments in partnership discussions and commercialization preparations for D-PLEX100.

Successful SHIELD II Phase III Trial Results

The SHIELD II Phase III trial demonstrated significant clinical benefits of D-PLEX100 in preventing surgical site infections (SSIs) in abdominal colorectal surgeries, with a statistically significant reduction of 38% in the primary endpoint and a 58% reduction in the rate of SSIs.

Strong Financial Position

PolyPid strengthened its balance sheet with cash and cash equivalents of $17.4 million and short-term deposits of $12 million, totaling $29.5 million, a significant improvement from $15.6 million as of December 31, 2024.

Positive Reception and Partnership Interest

D-PLEX100 generated substantial interest from potential commercial partners, healthcare professionals, and thought leaders, and there's increased interest from potential partners following Phase III results.

Progress in GLP-1 Program

Significant progress was made on the GLP-1 program aimed at addressing metabolic diseases, representing an exciting opportunity to expand PolyPid's therapeutic footprint.

PolyPid (PYPD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PYPD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.52 / -	-1.22	―	―	―
Aug 13, 2025	2025 (Q2)	-0.55 / -0.78	-1.25	37.60% (+0.47)	―
May 14, 2025	2025 (Q1)	-0.82 / -0.70	-1.37	48.91% (+0.67)	―
Feb 12, 2025	2024 (Q4)	-0.92 / -1.13	-3.97	71.54% (+2.84)	―
Nov 13, 2024	2024 (Q3)	-1.00 / -1.22	-3.4	64.12% (+2.18)	―
Aug 14, 2024	2024 (Q2)	-1.30 / -1.25	-3.9	67.95% (+2.65)	―
May 08, 2024	2024 (Q1)	-1.41 / -1.37	-8.4	83.69% (+7.03)	―
Feb 14, 2024	2023 (Q4)	-3.58 / -3.97	-9.6	58.65% (+5.63)	―	―
Nov 08, 2023	2023 (Q3)	-4.16 / -3.40	-14.4	76.39% (+11.00)	―	―
Aug 09, 2023	2023 (Q2)	-9.21 / -3.90	-18.3	78.69% (+14.40)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PYPD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$3.42	$3.49	+2.05%
May 14, 2025	$2.71	$2.90	+7.01%
Feb 12, 2025	$2.88	$2.97	+3.13%
Nov 13, 2024	$3.50	$3.40	-2.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PolyPid Ltd. (PYPD) report earnings?

PolyPid Ltd. (PYPD) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is PolyPid Ltd. (PYPD) earnings time?

PolyPid Ltd. (PYPD) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PYPD EPS forecast?

PYPD EPS forecast for the fiscal quarter 2025 (Q3) is -0.52.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing